1 MRC Holland BV

Amsterdam, Netherlands

1 MRC Holland BV

Amsterdam, Netherlands
SEARCH FILTERS
Time filter
Source Type

PubMed | 1 MRC Holland BV, VU University Amsterdam, Amphia Hospital and Hematology and Immunology
Type: Journal Article | Journal: Genetic testing and molecular biomarkers | Year: 2016

Genotyping of HLA-DQ2.2, HLA-DQ2.5, and HLA-DQ8 is important in celiac disease (CD). The absence of these three genotypes has a strong negative predictive value.We designed multiplex ligation-dependent probe amplification (MLPA) for the combined detection of HLA-DQ2.2, HLA-DQ2.5, and HLA-DQ8. The MLPA probe mix was validated against a set of 59 samples characterized by conventional techniques.The MLPA assay genotyped all 59 samples correctly when compared to the results obtained by PCR-SSCP/HD or PCR-SSO and PCR-SSP.The MLPA assay provides a reliable single-reaction analysis of the CD risk genotypes HLA-DQ2.2, HLA-DQ2.5, and HLA-DQ8 allowing for stratification or exclusion of disease risk.

Loading 1 MRC Holland BV collaborators
Loading 1 MRC Holland BV collaborators